You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBexarotene
Accession NumberDB00307  (APRD00114)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionBexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. [Wikipedia]
Structure
Thumb
Synonyms
4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid
4-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl]benzoic acid
Bexaroten
Bexarotène
Bexarotene
Bexaroteno
Bexarotenum
P-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid
p-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl]benzoic acid
Targretyn
Targrexin
External Identifiers
  • LG 100069
  • LGD 1069
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bexarotenecapsule, liquid filled75 mg/1oralOceanside Pharmaceuticals1999-12-29Not applicableUs
Targretingel1 g/100gtopicalValeant Pharmaceuticals North America LLC2000-06-28Not applicableUs
Targretincapsule, liquid filled75 mg/1oralValeant Pharmaceuticals North America LLC1999-12-29Not applicableUs
TargretinCapsule, soft75 mgOral useEisai Ltd2001-03-29Not applicableEu
Targretincapsule, liquid filled75 mg/1oralEisai Inc.1999-12-29Not applicableUs
Targretingel1 g/100gtopicalEisai Inc.2000-06-28Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bexarotenecapsule, liquid filled75 mg/1oralMylan Pharmaceuticals Inc.2015-07-09Not applicableUs
Bexarotenecapsule, liquid filled75 mg/1oralMylan Institutional Inc.2016-04-15Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIA61RXM4375
CAS number153559-49-0
WeightAverage: 348.4779
Monoisotopic: 348.20893014
Chemical FormulaC24H28O2
InChI KeyInChIKey=NAVMQTYZDKMPEU-UHFFFAOYSA-N
InChI
InChI=1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26)
IUPAC Name
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid
SMILES
CC1=CC2=C(C=C1C(=C)C1=CC=C(C=C1)C(O)=O)C(C)(C)CCC2(C)C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as retinoids. These are oxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassPrenol lipids
Sub ClassRetinoids
Direct ParentRetinoids
Alternative Parents
Substituents
  • Bexarotene
  • Bisabolane sesquiterpenoid
  • Sesquiterpenoid
  • Tetralin
  • Phenylpropene
  • Benzoic acid
  • Benzoic acid or derivatives
  • Styrene
  • Benzoyl
  • Benzenoid
  • Monocyclic benzene moiety
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationUsed orally for the treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. Also used topically for the treatment of skin lesions in early (stage IA and IB) CTCL in patients who experience refractory or persistent disease with the use of other therapies or are intolerant of other therapies.
PharmacodynamicsBexarotene is a member of a subclass of retinoids that selectively activate retinoid X receptors (RXRs). These retinoid receptors have biologic activity distinct from that of retinoic acid receptors (RARs). Bexarotene is indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. Bexarotene selectively binds and activates retinoid X receptor subtypes (RXRα, RXRβ, RXRγ). RXRs can form heterodimers with various receptor partners such as retinoic acid receptors (RARs), vitamin D receptor, thyroid receptor, and peroxisome proliferator activator receptors (PPARs). Once activated, these receptors function as transcription factors that regulate the expression of genes that control cellular differentiation and proliferation. Bexarotene inhibits the growth in vitro of some tumor cell lines of hematopoietic and squamous cell origin. It also induces tumor regression in vivo in some animal models.
Mechanism of actionBexarotene selectively binds with and activates retinoid X receptor subtypes. There are three subtypes in total: RXRα, RXRβ, RXRγ. The exact mechanism of action of bexarotene in the treatment of CTCL is unknown but the drug has activity in all clinical stages of CTCL.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding>99%
MetabolismNot Available
Route of eliminationUrinary elimination of bexarotene and its known metabolites is a minor excretory pathway (<1% of administered dose).
Half life7 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9954
Blood Brain Barrier+0.9022
Caco-2 permeable+0.794
P-glycoprotein substrateSubstrate0.6283
P-glycoprotein inhibitor INon-inhibitor0.5369
P-glycoprotein inhibitor IINon-inhibitor0.7182
Renal organic cation transporterNon-inhibitor0.8496
CYP450 2C9 substrateNon-substrate0.7722
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6786
CYP450 1A2 substrateNon-inhibitor0.8171
CYP450 2C9 inhibitorNon-inhibitor0.8724
CYP450 2D6 inhibitorInhibitor0.5589
CYP450 2C19 inhibitorInhibitor0.8351
CYP450 3A4 inhibitorNon-inhibitor0.8138
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6458
Ames testNon AMES toxic0.8592
CarcinogenicityNon-carcinogens0.7898
BiodegradationNot ready biodegradable0.933
Rat acute toxicity2.2119 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9703
hERG inhibition (predictor II)Non-inhibitor0.9034
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Eisai inc
Packagers
Dosage forms
FormRouteStrength
Capsule, liquid filledoral75 mg/1
Capsule, softOral use75 mg
Geltopical1 g/100g
Prices
Unit descriptionCostUnit
Targretin 75 mg capsule38.0USD capsule
Targretin 75 mg softgel36.54USD softget capsule
Targretin 1% gel30.08USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5780676 No1995-07-142015-07-14Us
US5962731 No1996-10-052016-10-05Us
US6043279 No1995-04-222012-04-22Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP6.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000149 mg/mLALOGPS
logP6.86ALOGPS
logP6.94ChemAxon
logS-6.4ALOGPS
pKa (Strongest Acidic)4.07ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity117.12 m3·mol-1ChemAxon
Polarizability40.89 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

DrugSyn.org

US5466861
General References
  1. Gniadecki R, Assaf C, Bagot M, Dummer R, Duvic M, Knobler R, Ranki A, Schwandt P, Whittaker S: The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol. 2007 Sep;157(3):433-40. Epub 2007 Jun 6. [PubMed:17553039 ]
  2. Dragnev KH, Petty WJ, Shah SJ, Lewis LD, Black CC, Memoli V, Nugent WC, Hermann T, Negro-Vilar A, Rigas JR, Dmitrovsky E: A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer. Clin Cancer Res. 2007 Mar 15;13(6):1794-800. [PubMed:17363535 ]
  3. Smit JW, Stokkel MP, Pereira AM, Romijn JA, Visser TJ: Bexarotene-induced hypothyroidism: bexarotene stimulates the peripheral metabolism of thyroid hormones. J Clin Endocrinol Metab. 2007 Jul;92(7):2496-9. Epub 2007 Apr 17. [PubMed:17440015 ]
  4. Lowe MN, Plosker GL: Bexarotene. Am J Clin Dermatol. 2000 Jul-Aug;1(4):245-50; discussion 251-2. [PubMed:11702369 ]
  5. Yen WC, Prudente RY, Corpuz MR, Negro-Vilar A, Lamph WW: A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours. Br J Cancer. 2006 Mar 13;94(5):654-60. [PubMed:16495926 ]
  6. Farol LT, Hymes KB: Bexarotene: a clinical review. Expert Rev Anticancer Ther. 2004 Apr;4(2):180-8. [PubMed:15056048 ]
External Links
ATC CodesL01XX25
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (40.2 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Abiraterone can be decreased when it is combined with Bexarotene.
AbirateroneThe metabolism of Bexarotene can be decreased when combined with Abiraterone.
AcenocoumarolThe serum concentration of Acenocoumarol can be decreased when it is combined with Bexarotene.
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Bexarotene.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Bexarotene.
AdinazolamThe serum concentration of Adinazolam can be decreased when it is combined with Bexarotene.
AlbendazoleThe serum concentration of Albendazole can be decreased when it is combined with Bexarotene.
AlclometasoneThe serum concentration of Alclometasone can be decreased when it is combined with Bexarotene.
AlfentanilThe serum concentration of Alfentanil can be decreased when it is combined with Bexarotene.
AlfuzosinThe serum concentration of Alfuzosin can be decreased when it is combined with Bexarotene.
AliskirenThe serum concentration of Aliskiren can be decreased when it is combined with Bexarotene.
AllylestrenolThe serum concentration of Allylestrenol can be decreased when it is combined with Bexarotene.
AlmotriptanThe serum concentration of Almotriptan can be decreased when it is combined with Bexarotene.
AlogliptinThe serum concentration of Alogliptin can be decreased when it is combined with Bexarotene.
AlosetronThe serum concentration of Alosetron can be decreased when it is combined with Bexarotene.
AlprazolamThe serum concentration of Alprazolam can be decreased when it is combined with Bexarotene.
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Bexarotene.
AmbroxolThe serum concentration of Ambroxol can be decreased when it is combined with Bexarotene.
AminophenazoneThe serum concentration of Aminophenazone can be decreased when it is combined with Bexarotene.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Bexarotene.
AmiodaroneThe serum concentration of Amiodarone can be decreased when it is combined with Bexarotene.
AmiodaroneThe metabolism of Bexarotene can be decreased when combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Bexarotene.
AmlodipineThe serum concentration of Amlodipine can be decreased when it is combined with Bexarotene.
AmprenavirThe serum concentration of Amprenavir can be decreased when it is combined with Bexarotene.
AntipyrineThe serum concentration of Antipyrine can be decreased when it is combined with Bexarotene.
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Bexarotene.
ApremilastThe serum concentration of Apremilast can be decreased when it is combined with Bexarotene.
AprepitantThe serum concentration of Bexarotene can be increased when it is combined with Aprepitant.
AprepitantThe serum concentration of Aprepitant can be decreased when it is combined with Bexarotene.
ArgatrobanThe serum concentration of Argatroban can be decreased when it is combined with Bexarotene.
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Bexarotene.
ArtemetherThe serum concentration of Artemether can be decreased when it is combined with Bexarotene.
AsenapineThe serum concentration of Asenapine can be decreased when it is combined with Bexarotene.
AstemizoleThe serum concentration of Astemizole can be decreased when it is combined with Bexarotene.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Bexarotene.
AtazanavirThe metabolism of Bexarotene can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Bexarotene can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Bexarotene.
AvanafilThe serum concentration of Avanafil can be decreased when it is combined with Bexarotene.
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Bexarotene.
AzelastineThe serum concentration of Azelastine can be decreased when it is combined with Bexarotene.
AzithromycinThe serum concentration of Azithromycin can be decreased when it is combined with Bexarotene.
BanoxantroneThe serum concentration of Banoxantrone can be decreased when it is combined with Bexarotene.
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Bexarotene.
BenzphetamineThe serum concentration of Benzphetamine can be decreased when it is combined with Bexarotene.
Benzyl alcoholThe serum concentration of Benzyl alcohol can be decreased when it is combined with Bexarotene.
BevacizumabBevacizumab may increase the cardiotoxic activities of Bexarotene.
BezafibrateThe serum concentration of Bezafibrate can be decreased when it is combined with Bexarotene.
BicalutamideThe serum concentration of Bicalutamide can be decreased when it is combined with Bexarotene.
BisoprololThe serum concentration of Bisoprolol can be decreased when it is combined with Bexarotene.
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Bexarotene can be decreased when combined with Boceprevir.
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Bexarotene.
BortezomibThe metabolism of Bexarotene can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Bexarotene can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Bexarotene.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Bexarotene.
BrexpiprazoleThe serum concentration of Brexpiprazole can be decreased when it is combined with Bexarotene.
BrinzolamideThe serum concentration of Brinzolamide can be decreased when it is combined with Bexarotene.
BromazepamThe serum concentration of Bromazepam can be decreased when it is combined with Bexarotene.
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Bexarotene.
BrompheniramineThe serum concentration of Brompheniramine can be decreased when it is combined with Bexarotene.
BudesonideThe serum concentration of Budesonide can be decreased when it is combined with Bexarotene.
BupivacaineThe serum concentration of Bupivacaine can be decreased when it is combined with Bexarotene.
BuprenorphineThe serum concentration of Buprenorphine can be decreased when it is combined with Bexarotene.
BupropionThe serum concentration of Bupropion can be decreased when it is combined with Bexarotene.
BuspironeThe serum concentration of Buspirone can be decreased when it is combined with Bexarotene.
BusulfanThe serum concentration of Busulfan can be decreased when it is combined with Bexarotene.
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Bexarotene.
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bexarotene.
CabergolineThe serum concentration of Cabergoline can be decreased when it is combined with Bexarotene.
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Bexarotene.
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Bexarotene.
CalcitriolThe serum concentration of Calcitriol can be decreased when it is combined with Bexarotene.
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Bexarotene.
CapecitabineThe metabolism of Bexarotene can be decreased when combined with Capecitabine.
CarbamazepineThe serum concentration of Carbamazepine can be decreased when it is combined with Bexarotene.
CarbamazepineThe metabolism of Bexarotene can be increased when combined with Carbamazepine.
CarbinoxamineThe serum concentration of Carbinoxamine can be decreased when it is combined with Bexarotene.
CarboplatinThe serum concentration of Bexarotene can be increased when it is combined with Carboplatin.
CariprazineThe serum concentration of Cariprazine can be decreased when it is combined with Bexarotene.
CarvedilolThe serum concentration of Carvedilol can be decreased when it is combined with Bexarotene.
CelecoxibThe serum concentration of Celecoxib can be decreased when it is combined with Bexarotene.
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Bexarotene.
CephalexinThe serum concentration of Cephalexin can be decreased when it is combined with Bexarotene.
CeritinibThe serum concentration of Bexarotene can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Bexarotene.
CevimelineThe serum concentration of Cevimeline can be decreased when it is combined with Bexarotene.
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Bexarotene.
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Bexarotene.
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Bexarotene.
ChlorphenamineThe serum concentration of Chlorphenamine can be decreased when it is combined with Bexarotene.
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Bexarotene.
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be decreased when it is combined with Bexarotene.
CholecalciferolThe serum concentration of Cholecalciferol can be decreased when it is combined with Bexarotene.
CholecalciferolThe metabolism of Bexarotene can be decreased when combined with Cholecalciferol.
CiclesonideThe serum concentration of Ciclesonide can be decreased when it is combined with Bexarotene.
CilostazolThe serum concentration of Cilostazol can be decreased when it is combined with Bexarotene.
CinacalcetThe serum concentration of Cinacalcet can be decreased when it is combined with Bexarotene.
CisaprideThe serum concentration of Cisapride can be decreased when it is combined with Bexarotene.
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Bexarotene.
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Bexarotene.
ClarithromycinThe metabolism of Bexarotene can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Bexarotene can be decreased when combined with Clemastine.
ClindamycinThe serum concentration of Clindamycin can be decreased when it is combined with Bexarotene.
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Bexarotene.
ClofazimineThe serum concentration of Clofazimine can be decreased when it is combined with Bexarotene.
ClofibrateThe serum concentration of Clofibrate can be decreased when it is combined with Bexarotene.
clomethiazoleThe serum concentration of clomethiazole can be decreased when it is combined with Bexarotene.
ClomipramineThe serum concentration of Clomipramine can be decreased when it is combined with Bexarotene.
ClonazepamThe serum concentration of Clonazepam can be decreased when it is combined with Bexarotene.
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Bexarotene.
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Bexarotene.
ClorazepateThe serum concentration of Clorazepate can be decreased when it is combined with Bexarotene.
ClotiazepamThe serum concentration of Clotiazepam can be decreased when it is combined with Bexarotene.
ClotrimazoleThe metabolism of Bexarotene can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Bexarotene is combined with Clozapine.
CobicistatThe metabolism of Bexarotene can be decreased when combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Bexarotene.
CocaineThe serum concentration of Cocaine can be decreased when it is combined with Bexarotene.
CodeineThe serum concentration of Codeine can be decreased when it is combined with Bexarotene.
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Bexarotene.
ConivaptanThe serum concentration of Bexarotene can be increased when it is combined with Conivaptan.
ConivaptanThe serum concentration of Conivaptan can be decreased when it is combined with Bexarotene.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Bexarotene.
Cortisone acetateThe serum concentration of Cortisone acetate can be decreased when it is combined with Bexarotene.
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Bexarotene.
CrizotinibThe metabolism of Bexarotene can be decreased when combined with Crizotinib.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Bexarotene.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Bexarotene.
CyclophosphamideThe serum concentration of Cyclophosphamide can be decreased when it is combined with Bexarotene.
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Bexarotene.
CyclosporineThe metabolism of Bexarotene can be decreased when combined with Cyclosporine.
CytarabineThe serum concentration of Cytarabine can be decreased when it is combined with Bexarotene.
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Bexarotene.
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Bexarotene.
DantroleneThe serum concentration of Dantrolene can be decreased when it is combined with Bexarotene.
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Bexarotene.
DapsoneThe serum concentration of Dapsone can be decreased when it is combined with Bexarotene.
DarifenacinThe serum concentration of Darifenacin can be decreased when it is combined with Bexarotene.
DarunavirThe serum concentration of Darunavir can be decreased when it is combined with Bexarotene.
DarunavirThe metabolism of Bexarotene can be decreased when combined with Darunavir.
DasabuvirThe serum concentration of Dasabuvir can be decreased when it is combined with Bexarotene.
DasatinibThe serum concentration of Bexarotene can be increased when it is combined with Dasatinib.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Bexarotene.
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Bexarotene.
DeferasiroxThe serum concentration of Bexarotene can be decreased when it is combined with Deferasirox.
DehydroepiandrosteroneThe serum concentration of Dehydroepiandrosterone can be decreased when it is combined with Bexarotene.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Bexarotene.
DelavirdineThe metabolism of Bexarotene can be decreased when combined with Delavirdine.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Bexarotene.
DesvenlafaxineThe serum concentration of Desvenlafaxine can be decreased when it is combined with Bexarotene.
DexamethasoneThe serum concentration of Dexamethasone can be decreased when it is combined with Bexarotene.
DextromethorphanThe serum concentration of Dextromethorphan can be decreased when it is combined with Bexarotene.
DextropropoxypheneThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Bexarotene.
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Bexarotene.
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Bexarotene.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Bexarotene.
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Bexarotene.
DigoxinDigoxin may decrease the cardiotoxic activities of Bexarotene.
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Bexarotene.
DihydrocodeineThe serum concentration of Dihydrocodeine can be decreased when it is combined with Bexarotene.
DihydroergotamineThe serum concentration of Dihydroergotamine can be decreased when it is combined with Bexarotene.
DihydroergotamineThe metabolism of Bexarotene can be decreased when combined with Dihydroergotamine.
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Bexarotene.
DiltiazemThe metabolism of Bexarotene can be decreased when combined with Diltiazem.
DisopyramideThe serum concentration of Disopyramide can be decreased when it is combined with Bexarotene.
DisulfiramThe serum concentration of Disulfiram can be decreased when it is combined with Bexarotene.
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Bexarotene.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bexarotene.
DofetilideThe serum concentration of Dofetilide can be decreased when it is combined with Bexarotene.
DolasetronThe serum concentration of Dolasetron can be decreased when it is combined with Bexarotene.
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Bexarotene.
DonepezilThe serum concentration of Donepezil can be decreased when it is combined with Bexarotene.
DorzolamideThe serum concentration of Dorzolamide can be decreased when it is combined with Bexarotene.
DoxepinThe serum concentration of Doxepin can be decreased when it is combined with Bexarotene.
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Bexarotene.
DoxycyclineThe metabolism of Bexarotene can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be decreased when it is combined with Bexarotene.
DronedaroneThe serum concentration of Dronedarone can be decreased when it is combined with Bexarotene.
DronedaroneThe metabolism of Bexarotene can be decreased when combined with Dronedarone.
DutasterideThe serum concentration of Dutasteride can be decreased when it is combined with Bexarotene.
EfavirenzThe serum concentration of Efavirenz can be decreased when it is combined with Bexarotene.
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Bexarotene.
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Bexarotene.
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Bexarotene.
EnalaprilThe serum concentration of Enalapril can be decreased when it is combined with Bexarotene.
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Bexarotene.
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Bexarotene.
EplerenoneThe serum concentration of Eplerenone can be decreased when it is combined with Bexarotene.
ErgocalciferolThe serum concentration of Ergocalciferol can be decreased when it is combined with Bexarotene.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Bexarotene.
ErgonovineThe serum concentration of Ergonovine can be decreased when it is combined with Bexarotene.
ErgotamineThe serum concentration of Ergotamine can be decreased when it is combined with Bexarotene.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Bexarotene.
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Bexarotene.
ErythromycinThe metabolism of Bexarotene can be decreased when combined with Erythromycin.
EscitalopramThe serum concentration of Escitalopram can be decreased when it is combined with Bexarotene.
Eslicarbazepine acetateThe serum concentration of Bexarotene can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe serum concentration of Esomeprazole can be decreased when it is combined with Bexarotene.
EstazolamThe serum concentration of Estazolam can be decreased when it is combined with Bexarotene.
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Bexarotene.
Estradiol valerate/DienogestThe serum concentration of Estradiol valerate/Dienogest can be decreased when it is combined with Bexarotene.
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Bexarotene.
EstroneThe serum concentration of Estrone can be decreased when it is combined with Bexarotene.
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Bexarotene.
EszopicloneThe serum concentration of Eszopiclone can be decreased when it is combined with Bexarotene.
EthanolThe serum concentration of Ethanol can be decreased when it is combined with Bexarotene.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Bexarotene.
EthosuximideThe serum concentration of Ethosuximide can be decreased when it is combined with Bexarotene.
EthylmorphineThe serum concentration of Ethylmorphine can be decreased when it is combined with Bexarotene.
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Bexarotene.
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Bexarotene.
EtoricoxibThe serum concentration of Etoricoxib can be decreased when it is combined with Bexarotene.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Bexarotene.
EverolimusThe serum concentration of Everolimus can be decreased when it is combined with Bexarotene.
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Bexarotene.
FamciclovirThe serum concentration of Famciclovir can be decreased when it is combined with Bexarotene.
FelbamateThe serum concentration of Felbamate can be decreased when it is combined with Bexarotene.
FelodipineThe serum concentration of Felodipine can be decreased when it is combined with Bexarotene.
FenofibrateThe serum concentration of Fenofibrate can be decreased when it is combined with Bexarotene.
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Bexarotene.
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Bexarotene.
FinasterideThe serum concentration of Finasteride can be decreased when it is combined with Bexarotene.
FingolimodThe serum concentration of Fingolimod can be decreased when it is combined with Bexarotene.
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Bexarotene.
FloxuridineThe metabolism of Bexarotene can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Bexarotene can be decreased when combined with Fluconazole.
FlunisolideThe serum concentration of Flunisolide can be decreased when it is combined with Bexarotene.
FlunitrazepamThe serum concentration of Flunitrazepam can be decreased when it is combined with Bexarotene.
FluorometholoneThe serum concentration of Fluorometholone can be decreased when it is combined with Bexarotene.
FluorouracilThe metabolism of Bexarotene can be decreased when combined with Fluorouracil.
FluoxetineThe serum concentration of Fluoxetine can be decreased when it is combined with Bexarotene.
FlurazepamThe serum concentration of Flurazepam can be decreased when it is combined with Bexarotene.
FlutamideThe serum concentration of Flutamide can be decreased when it is combined with Bexarotene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Bexarotene.
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be decreased when it is combined with Bexarotene.
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Bexarotene.
FluvastatinThe metabolism of Bexarotene can be decreased when combined with Fluvastatin.
FluvoxamineThe metabolism of Bexarotene can be decreased when combined with Fluvoxamine.
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Bexarotene.
FosamprenavirThe metabolism of Bexarotene can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Bexarotene can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Bexarotene can be increased when combined with Fosphenytoin.
FulvestrantThe serum concentration of Fulvestrant can be decreased when it is combined with Bexarotene.
Fusidic AcidThe serum concentration of Bexarotene can be increased when it is combined with Fusidic Acid.
GalantamineThe serum concentration of Galantamine can be decreased when it is combined with Bexarotene.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Bexarotene.
GemfibrozilThe serum concentration of Bexarotene can be increased when it is combined with Gemfibrozil.
GemfibrozilThe serum concentration of Gemfibrozil can be decreased when it is combined with Bexarotene.
GlipizideThe serum concentration of Glipizide can be decreased when it is combined with Bexarotene.
GlyburideThe serum concentration of Glyburide can be decreased when it is combined with Bexarotene.
GranisetronThe serum concentration of Granisetron can be decreased when it is combined with Bexarotene.
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Bexarotene.
GuanfacineThe serum concentration of Guanfacine can be decreased when it is combined with Bexarotene.
HalofantrineThe serum concentration of Halofantrine can be decreased when it is combined with Bexarotene.
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Bexarotene.
HalothaneThe serum concentration of Halothane can be decreased when it is combined with Bexarotene.
HexobarbitalThe serum concentration of Hexobarbital can be decreased when it is combined with Bexarotene.
Histamine PhosphateThe serum concentration of Histamine Phosphate can be decreased when it is combined with Bexarotene.
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Bexarotene.
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Bexarotene.
HydromorphoneThe serum concentration of Hydromorphone can be decreased when it is combined with Bexarotene.
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Bexarotene.
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Bexarotene.
IdelalisibThe serum concentration of Bexarotene can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Bexarotene resulting in a loss in efficacy.
IloperidoneThe serum concentration of Iloperidone can be decreased when it is combined with Bexarotene.
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Bexarotene.
ImatinibThe metabolism of Bexarotene can be decreased when combined with Imatinib.
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Bexarotene.
ImiquimodThe serum concentration of Imiquimod can be decreased when it is combined with Bexarotene.
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Bexarotene.
IndapamideThe serum concentration of Indapamide can be decreased when it is combined with Bexarotene.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Bexarotene.
IndinavirThe metabolism of Bexarotene can be decreased when combined with Indinavir.
Ipratropium bromideThe serum concentration of Ipratropium bromide can be decreased when it is combined with Bexarotene.
IrbesartanThe metabolism of Bexarotene can be decreased when combined with Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Bexarotene.
IsavuconazoniumThe serum concentration of Isavuconazonium can be decreased when it is combined with Bexarotene.
IsavuconazoniumThe metabolism of Bexarotene can be decreased when combined with Isavuconazonium.
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Bexarotene.
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Bexarotene.
IsradipineThe serum concentration of Isradipine can be decreased when it is combined with Bexarotene.
IsradipineThe metabolism of Bexarotene can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Bexarotene.
ItraconazoleThe metabolism of Bexarotene can be decreased when combined with Itraconazole.
IvabradineThe serum concentration of Ivabradine can be decreased when it is combined with Bexarotene.
IvacaftorThe serum concentration of Bexarotene can be increased when it is combined with Ivacaftor.
IvacaftorThe serum concentration of Ivacaftor can be decreased when it is combined with Bexarotene.
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Bexarotene.
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Bexarotene.
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Bexarotene.
KetamineThe serum concentration of Ketamine can be decreased when it is combined with Bexarotene.
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Bexarotene.
KetobemidoneThe serum concentration of Ketobemidone can be decreased when it is combined with Bexarotene.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Bexarotene.
KetoconazoleThe metabolism of Bexarotene can be decreased when combined with Ketoconazole.
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Bexarotene.
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Bexarotene.
LaquinimodThe serum concentration of Laquinimod can be decreased when it is combined with Bexarotene.
LeflunomideThe metabolism of Bexarotene can be decreased when combined with Leflunomide.
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Bexarotene.
LercanidipineThe serum concentration of Lercanidipine can be decreased when it is combined with Bexarotene.
LetrozoleThe serum concentration of Letrozole can be decreased when it is combined with Bexarotene.
LevobupivacaineThe serum concentration of Levobupivacaine can be decreased when it is combined with Bexarotene.
LevocetirizineThe serum concentration of Levocetirizine can be decreased when it is combined with Bexarotene.
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Bexarotene.
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Bexarotene.
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Bexarotene.
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Bexarotene.
LidocaineThe serum concentration of Lidocaine can be decreased when it is combined with Bexarotene.
LisurideThe serum concentration of Lisuride can be decreased when it is combined with Bexarotene.
LomitapideThe serum concentration of Lomitapide can be decreased when it is combined with Bexarotene.
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Bexarotene.
LopinavirThe serum concentration of Lopinavir can be decreased when it is combined with Bexarotene.
LopinavirThe metabolism of Bexarotene can be decreased when combined with Lopinavir.
LoratadineThe serum concentration of Loratadine can be decreased when it is combined with Bexarotene.
LorcaserinThe serum concentration of Lorcaserin can be decreased when it is combined with Bexarotene.
LosartanThe serum concentration of Losartan can be decreased when it is combined with Bexarotene.
LosartanThe metabolism of Bexarotene can be decreased when combined with Losartan.
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Bexarotene.
LovastatinThe metabolism of Bexarotene can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Bexarotene can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Bexarotene can be decreased when it is combined with Lumacaftor.
LumefantrineThe serum concentration of Lumefantrine can be decreased when it is combined with Bexarotene.
LurasidoneThe serum concentration of Lurasidone can be decreased when it is combined with Bexarotene.
MacitentanThe serum concentration of Macitentan can be decreased when it is combined with Bexarotene.
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Bexarotene.
MebendazoleThe serum concentration of Mebendazole can be decreased when it is combined with Bexarotene.
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Bexarotene.
MefloquineThe serum concentration of Mefloquine can be decreased when it is combined with Bexarotene.
MeloxicamThe serum concentration of Meloxicam can be decreased when it is combined with Bexarotene.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Bexarotene.
MethadoneThe serum concentration of Methadone can be decreased when it is combined with Bexarotene.
MethaqualoneThe serum concentration of Methaqualone can be decreased when it is combined with Bexarotene.
MethoxsalenThe serum concentration of Methoxsalen can be decreased when it is combined with Bexarotene.
MethoxyfluraneThe serum concentration of Methoxyflurane can be decreased when it is combined with Bexarotene.
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Bexarotene.
MethyltestosteroneThe serum concentration of Methyltestosterone can be decreased when it is combined with Bexarotene.
MetronidazoleThe serum concentration of Metronidazole can be decreased when it is combined with Bexarotene.
MexiletineThe serum concentration of Mexiletine can be decreased when it is combined with Bexarotene.
MianserinThe serum concentration of Mianserin can be decreased when it is combined with Bexarotene.
MibefradilThe serum concentration of Mibefradil can be decreased when it is combined with Bexarotene.
MiconazoleThe serum concentration of Miconazole can be decreased when it is combined with Bexarotene.
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Bexarotene.
MifepristoneThe serum concentration of Mifepristone can be decreased when it is combined with Bexarotene.
MifepristoneThe metabolism of Bexarotene can be decreased when combined with Mifepristone.
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Bexarotene.
MirtazapineThe serum concentration of Mirtazapine can be decreased when it is combined with Bexarotene.
MitotaneThe serum concentration of Bexarotene can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Modafinil can be decreased when it is combined with Bexarotene.
MontelukastThe serum concentration of Montelukast can be decreased when it is combined with Bexarotene.
MorphineThe serum concentration of Morphine can be decreased when it is combined with Bexarotene.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Bexarotene.
NafcillinThe serum concentration of Bexarotene can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be decreased when it is combined with Bexarotene.
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Bexarotene.
NateglinideThe serum concentration of Nateglinide can be decreased when it is combined with Bexarotene.
NefazodoneThe serum concentration of Nefazodone can be decreased when it is combined with Bexarotene.
NefazodoneThe metabolism of Bexarotene can be decreased when combined with Nefazodone.
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Bexarotene.
NelfinavirThe metabolism of Bexarotene can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Bexarotene can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Nevirapine can be decreased when it is combined with Bexarotene.
NevirapineThe metabolism of Bexarotene can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Bexarotene.
NicardipineThe metabolism of Bexarotene can be decreased when combined with Nicardipine.
NicotineThe serum concentration of Nicotine can be decreased when it is combined with Bexarotene.
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Bexarotene.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Bexarotene.
NilotinibThe metabolism of Bexarotene can be decreased when combined with Nilotinib.
NilvadipineThe serum concentration of Nilvadipine can be decreased when it is combined with Bexarotene.
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Bexarotene.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Bexarotene.
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Bexarotene.
NitrazepamThe serum concentration of Nitrazepam can be decreased when it is combined with Bexarotene.
NitrendipineThe serum concentration of Nitrendipine can be decreased when it is combined with Bexarotene.
NorethisteroneThe serum concentration of Norethisterone can be decreased when it is combined with Bexarotene.
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Bexarotene.
NortriptylineThe serum concentration of Nortriptyline can be decreased when it is combined with Bexarotene.
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Bexarotene.
OlaparibThe metabolism of Bexarotene can be decreased when combined with Olaparib.
OlopatadineThe serum concentration of Olopatadine can be decreased when it is combined with Bexarotene.
OmeprazoleThe serum concentration of Omeprazole can be decreased when it is combined with Bexarotene.
OmeprazoleThe metabolism of Bexarotene can be decreased when combined with Omeprazole.
OndansetronThe serum concentration of Ondansetron can be decreased when it is combined with Bexarotene.
OrphenadrineThe serum concentration of Orphenadrine can be decreased when it is combined with Bexarotene.
OsimertinibThe serum concentration of Bexarotene can be increased when it is combined with Osimertinib.
OspemifeneThe serum concentration of Ospemifene can be decreased when it is combined with Bexarotene.
OuabainOuabain may decrease the cardiotoxic activities of Bexarotene.
OxazepamThe serum concentration of Oxazepam can be decreased when it is combined with Bexarotene.
OxybutyninThe serum concentration of Oxybutynin can be decreased when it is combined with Bexarotene.
OxycodoneThe serum concentration of Oxycodone can be decreased when it is combined with Bexarotene.
OxymorphoneThe serum concentration of Oxymorphone can be decreased when it is combined with Bexarotene.
PaclitaxelThe serum concentration of Bexarotene can be increased when it is combined with Paclitaxel.
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Bexarotene.
PalbociclibThe serum concentration of Bexarotene can be increased when it is combined with Palbociclib.
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Bexarotene.
PalonosetronThe serum concentration of Palonosetron can be decreased when it is combined with Bexarotene.
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Bexarotene.
PantoprazoleThe serum concentration of Pantoprazole can be decreased when it is combined with Bexarotene.
ParamethadioneThe serum concentration of Paramethadione can be decreased when it is combined with Bexarotene.
ParamethasoneThe serum concentration of Paramethasone can be decreased when it is combined with Bexarotene.
ParecoxibThe serum concentration of Parecoxib can be decreased when it is combined with Bexarotene.
ParicalcitolThe serum concentration of Paricalcitol can be decreased when it is combined with Bexarotene.
ParitaprevirThe serum concentration of Paritaprevir can be decreased when it is combined with Bexarotene.
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Bexarotene.
PentamidineThe serum concentration of Pentamidine can be decreased when it is combined with Bexarotene.
PentobarbitalThe metabolism of Bexarotene can be increased when combined with Pentobarbital.
PerampanelThe serum concentration of Perampanel can be decreased when it is combined with Bexarotene.
PergolideThe serum concentration of Pergolide can be decreased when it is combined with Bexarotene.
PerhexilineThe serum concentration of Perhexiline can be decreased when it is combined with Bexarotene.
PermethrinThe serum concentration of Permethrin can be decreased when it is combined with Bexarotene.
PerphenazineThe serum concentration of Perphenazine can be decreased when it is combined with Bexarotene.
PethidineThe serum concentration of Pethidine can be decreased when it is combined with Bexarotene.
PhenacetinThe serum concentration of Phenacetin can be decreased when it is combined with Bexarotene.
PhenobarbitalThe metabolism of Bexarotene can be increased when combined with Phenobarbital.
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be decreased when it is combined with Bexarotene.
PhenprocoumonThe serum concentration of Phenprocoumon can be decreased when it is combined with Bexarotene.
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Bexarotene.
PhenytoinThe metabolism of Bexarotene can be increased when combined with Phenytoin.
PilocarpineThe serum concentration of Pilocarpine can be decreased when it is combined with Bexarotene.
PimecrolimusThe serum concentration of Pimecrolimus can be decreased when it is combined with Bexarotene.
PimozideThe serum concentration of Pimozide can be decreased when it is combined with Bexarotene.
PinacidilThe serum concentration of Pinacidil can be decreased when it is combined with Bexarotene.
PioglitazoneThe serum concentration of Pioglitazone can be decreased when it is combined with Bexarotene.
PipotiazineThe serum concentration of Pipotiazine can be decreased when it is combined with Bexarotene.
PodofiloxThe serum concentration of Podofilox can be decreased when it is combined with Bexarotene.
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Bexarotene.
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Bexarotene.
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Bexarotene.
PosaconazoleThe metabolism of Bexarotene can be decreased when combined with Posaconazole.
PrasugrelThe serum concentration of Prasugrel can be decreased when it is combined with Bexarotene.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Bexarotene.
PrazepamThe serum concentration of Prazepam can be decreased when it is combined with Bexarotene.
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Bexarotene.
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Bexarotene.
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Bexarotene.
PrimaquineThe serum concentration of Primaquine can be decreased when it is combined with Bexarotene.
PrimidoneThe metabolism of Bexarotene can be increased when combined with Primidone.
ProchlorperazineThe serum concentration of Prochlorperazine can be decreased when it is combined with Bexarotene.
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Bexarotene.
ProguanilThe serum concentration of Proguanil can be decreased when it is combined with Bexarotene.
PromazineThe serum concentration of Promazine can be decreased when it is combined with Bexarotene.
PropafenoneThe serum concentration of Propafenone can be decreased when it is combined with Bexarotene.
PropofolThe serum concentration of Propofol can be decreased when it is combined with Bexarotene.
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Bexarotene.
PyrazinamideThe serum concentration of Pyrazinamide can be decreased when it is combined with Bexarotene.
PyrimethamineThe metabolism of Bexarotene can be decreased when combined with Pyrimethamine.
QuazepamThe serum concentration of Quazepam can be decreased when it is combined with Bexarotene.
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Bexarotene.
QuinacrineThe serum concentration of Quinacrine can be decreased when it is combined with Bexarotene.
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Bexarotene.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Bexarotene.
QuinineThe metabolism of Bexarotene can be decreased when combined with Quinine.
RabeprazoleThe serum concentration of Rabeprazole can be decreased when it is combined with Bexarotene.
RaloxifeneThe serum concentration of Raloxifene can be decreased when it is combined with Bexarotene.
RamelteonThe serum concentration of Ramelteon can be decreased when it is combined with Bexarotene.
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Bexarotene.
RanolazineThe metabolism of Bexarotene can be decreased when combined with Ranolazine.
ReboxetineThe serum concentration of Reboxetine can be decreased when it is combined with Bexarotene.
RegorafenibThe serum concentration of Regorafenib can be decreased when it is combined with Bexarotene.
RepaglinideThe serum concentration of Repaglinide can be decreased when it is combined with Bexarotene.
RetapamulinThe serum concentration of Retapamulin can be decreased when it is combined with Bexarotene.
RifabutinThe serum concentration of Rifabutin can be decreased when it is combined with Bexarotene.
RifabutinThe metabolism of Bexarotene can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Rifampicin can be decreased when it is combined with Bexarotene.
RifampicinThe metabolism of Bexarotene can be increased when combined with Rifampicin.
RifapentineThe metabolism of Bexarotene can be increased when combined with Rifapentine.
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Bexarotene.
RimonabantThe serum concentration of Rimonabant can be decreased when it is combined with Bexarotene.
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Bexarotene.
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Bexarotene.
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Bexarotene.
RitonavirThe metabolism of Bexarotene can be decreased when combined with Ritonavir.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Bexarotene.
RofecoxibThe serum concentration of Rofecoxib can be decreased when it is combined with Bexarotene.
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Bexarotene.
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Bexarotene.
RopiniroleThe serum concentration of Ropinirole can be decreased when it is combined with Bexarotene.
RopivacaineThe serum concentration of Ropivacaine can be decreased when it is combined with Bexarotene.
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Bexarotene.
RotigotineThe serum concentration of Rotigotine can be decreased when it is combined with Bexarotene.
RoxithromycinThe serum concentration of Roxithromycin can be decreased when it is combined with Bexarotene.
RuxolitinibThe serum concentration of Ruxolitinib can be decreased when it is combined with Bexarotene.
SalmeterolThe serum concentration of Salmeterol can be decreased when it is combined with Bexarotene.
SaquinavirThe serum concentration of Saquinavir can be decreased when it is combined with Bexarotene.
SaquinavirThe metabolism of Bexarotene can be decreased when combined with Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Bexarotene.
SecobarbitalThe metabolism of Bexarotene can be increased when combined with Secobarbital.
SelegilineThe serum concentration of Selegiline can be decreased when it is combined with Bexarotene.
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Bexarotene.
SeratrodastThe serum concentration of Seratrodast can be decreased when it is combined with Bexarotene.
SertindoleThe serum concentration of Sertindole can be decreased when it is combined with Bexarotene.
SertralineThe serum concentration of Sertraline can be decreased when it is combined with Bexarotene.
SevofluraneThe serum concentration of Sevoflurane can be decreased when it is combined with Bexarotene.
SibutramineThe serum concentration of Sibutramine can be decreased when it is combined with Bexarotene.
SildenafilThe serum concentration of Sildenafil can be decreased when it is combined with Bexarotene.
SildenafilThe metabolism of Bexarotene can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be decreased when it is combined with Bexarotene.
SiltuximabThe serum concentration of Bexarotene can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Bexarotene can be increased when it is combined with Simeprevir.
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Bexarotene.
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Bexarotene.
SirolimusThe serum concentration of Sirolimus can be decreased when it is combined with Bexarotene.
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Bexarotene.
SolifenacinThe serum concentration of Solifenacin can be decreased when it is combined with Bexarotene.
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Bexarotene.
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Bexarotene.
SorafenibThe metabolism of Bexarotene can be decreased when combined with Sorafenib.
SpiramycinThe serum concentration of Spiramycin can be decreased when it is combined with Bexarotene.
St. John's WortThe serum concentration of Bexarotene can be decreased when it is combined with St. John&#39;s Wort.
StiripentolThe serum concentration of Bexarotene can be increased when it is combined with Stiripentol.
SufentanilThe serum concentration of Sufentanil can be decreased when it is combined with Bexarotene.
SulfadiazineThe serum concentration of Sulfadiazine can be decreased when it is combined with Bexarotene.
SulfadiazineThe metabolism of Bexarotene can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Bexarotene.
SulfamethoxazoleThe metabolism of Bexarotene can be decreased when combined with Sulfamethoxazole.
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Bexarotene.
SulfisoxazoleThe metabolism of Bexarotene can be decreased when combined with Sulfisoxazole.
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Bexarotene.
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Bexarotene.
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Bexarotene.
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Bexarotene.
TadalafilThe serum concentration of Tadalafil can be decreased when it is combined with Bexarotene.
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Bexarotene.
TamsulosinThe serum concentration of Tamsulosin can be decreased when it is combined with Bexarotene.
TasosartanThe serum concentration of Tasosartan can be decreased when it is combined with Bexarotene.
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be decreased when it is combined with Bexarotene.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Bexarotene.
TelaprevirThe metabolism of Bexarotene can be decreased when combined with Telaprevir.
TelithromycinThe serum concentration of Telithromycin can be decreased when it is combined with Bexarotene.
TelithromycinThe metabolism of Bexarotene can be decreased when combined with Telithromycin.
TemazepamThe serum concentration of Temazepam can be decreased when it is combined with Bexarotene.
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Bexarotene.
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Bexarotene.
TerbinafineThe serum concentration of Terbinafine can be decreased when it is combined with Bexarotene.
TerfenadineThe serum concentration of Terfenadine can be decreased when it is combined with Bexarotene.
TesmilifeneThe serum concentration of Tesmilifene can be decreased when it is combined with Bexarotene.
TestosteroneThe serum concentration of Testosterone can be decreased when it is combined with Bexarotene.
TetracyclineThe serum concentration of Tetracycline can be decreased when it is combined with Bexarotene.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Bexarotene.
ThiotepaThe serum concentration of Thiotepa can be decreased when it is combined with Bexarotene.
TiagabineThe serum concentration of Tiagabine can be decreased when it is combined with Bexarotene.
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Bexarotene.
TicagrelorThe metabolism of Bexarotene can be decreased when combined with Ticagrelor.
TiclopidineThe serum concentration of Ticlopidine can be decreased when it is combined with Bexarotene.
TiclopidineThe metabolism of Bexarotene can be decreased when combined with Ticlopidine.
TinidazoleThe serum concentration of Tinidazole can be decreased when it is combined with Bexarotene.
TiotropiumThe serum concentration of Tiotropium can be decreased when it is combined with Bexarotene.
TipranavirThe serum concentration of Tipranavir can be decreased when it is combined with Bexarotene.
TocilizumabThe serum concentration of Bexarotene can be decreased when it is combined with Tocilizumab.
TofacitinibThe serum concentration of Tofacitinib can be decreased when it is combined with Bexarotene.
TolbutamideThe metabolism of Bexarotene can be decreased when combined with Tolbutamide.
TolterodineThe serum concentration of Tolterodine can be decreased when it is combined with Bexarotene.
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Bexarotene.
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Bexarotene.
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Bexarotene.
TramadolThe serum concentration of Tramadol can be decreased when it is combined with Bexarotene.
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Bexarotene.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Bexarotene.
TrazodoneThe serum concentration of Trazodone can be decreased when it is combined with Bexarotene.
TretinoinThe serum concentration of Tretinoin can be decreased when it is combined with Bexarotene.
TriamcinoloneThe serum concentration of Triamcinolone can be decreased when it is combined with Bexarotene.
TriazolamThe serum concentration of Triazolam can be decreased when it is combined with Bexarotene.
TrimethadioneThe serum concentration of Trimethadione can be decreased when it is combined with Bexarotene.
TrimethoprimThe serum concentration of Trimethoprim can be decreased when it is combined with Bexarotene.
TrimethoprimThe metabolism of Bexarotene can be decreased when combined with Trimethoprim.
TrimipramineThe serum concentration of Trimipramine can be decreased when it is combined with Bexarotene.
TroglitazoneThe serum concentration of Troglitazone can be decreased when it is combined with Bexarotene.
TroleandomycinThe serum concentration of Troleandomycin can be decreased when it is combined with Bexarotene.
UdenafilThe serum concentration of Udenafil can be decreased when it is combined with Bexarotene.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Bexarotene.
ValdecoxibThe serum concentration of Valdecoxib can be decreased when it is combined with Bexarotene.
Valproic AcidThe metabolism of Bexarotene can be decreased when combined with Valproic Acid.
ValsartanThe metabolism of Bexarotene can be decreased when combined with Valsartan.
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Bexarotene.
VanoxerineThe serum concentration of Vanoxerine can be decreased when it is combined with Bexarotene.
VardenafilThe serum concentration of Vardenafil can be decreased when it is combined with Bexarotene.
VemurafenibThe serum concentration of Vemurafenib can be decreased when it is combined with Bexarotene.
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Bexarotene.
VenlafaxineThe metabolism of Bexarotene can be decreased when combined with Venlafaxine.
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Bexarotene.
VerapamilThe metabolism of Bexarotene can be decreased when combined with Verapamil.
VicrivirocThe serum concentration of Vicriviroc can be decreased when it is combined with Bexarotene.
VilanterolThe serum concentration of Vilanterol can be decreased when it is combined with Bexarotene.
VilazodoneThe serum concentration of Vilazodone can be decreased when it is combined with Bexarotene.
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Bexarotene.
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Bexarotene.
VindesineThe serum concentration of Vindesine can be decreased when it is combined with Bexarotene.
VinorelbineThe serum concentration of Vinorelbine can be decreased when it is combined with Bexarotene.
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Bexarotene.
Vitamin AThe risk or severity of adverse effects can be increased when Vitamin A is combined with Bexarotene.
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Bexarotene.
VoriconazoleThe metabolism of Bexarotene can be decreased when combined with Voriconazole.
VortioxetineThe serum concentration of Vortioxetine can be decreased when it is combined with Bexarotene.
WarfarinThe serum concentration of Warfarin can be decreased when it is combined with Bexarotene.
YohimbineThe serum concentration of Yohimbine can be decreased when it is combined with Bexarotene.
ZafirlukastThe serum concentration of Zafirlukast can be decreased when it is combined with Bexarotene.
ZafirlukastThe metabolism of Bexarotene can be decreased when combined with Zafirlukast.
ZalcitabineThe serum concentration of Zalcitabine can be decreased when it is combined with Bexarotene.
ZaleplonThe serum concentration of Zaleplon can be decreased when it is combined with Bexarotene.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Bexarotene.
ZileutonThe serum concentration of Zileuton can be decreased when it is combined with Bexarotene.
ZiprasidoneThe serum concentration of Ziprasidone can be decreased when it is combined with Bexarotene.
ZiprasidoneThe metabolism of Bexarotene can be decreased when combined with Ziprasidone.
ZolpidemThe serum concentration of Zolpidem can be decreased when it is combined with Bexarotene.
ZomepiracThe serum concentration of Zomepirac can be decreased when it is combined with Bexarotene.
ZonisamideThe serum concentration of Zonisamide can be decreased when it is combined with Bexarotene.
ZopicloneThe serum concentration of Zopiclone can be decreased when it is combined with Bexarotene.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. The high affinity ligand for RXR...
Gene Name:
RXRA
Uniprot ID:
P19793
Molecular Weight:
50810.835 Da
References
  1. Lowe MN, Plosker GL: Bexarotene. Am J Clin Dermatol. 2000 Jul-Aug;1(4):245-50; discussion 251-2. [PubMed:11702369 ]
  2. Tsai DE, Luger SM, Andreadis C, Vogl DT, Kemner A, Potuzak M, Goradia A, Loren AW, Perl AE, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Thompson JE, Swider C, Bagg A, Mato AR, Carroll M: A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia. Clin Cancer Res. 2008 Sep 1;14(17):5619-25. doi: 10.1158/1078-0432.CCR-07-5185. [PubMed:18765556 ]
  3. Tooker P, Yen WC, Ng SC, Negro-Vilar A, Hermann TW: Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification. Cancer Res. 2007 May 1;67(9):4425-33. [PubMed:17483357 ]
  4. Lalloyer F, Fievet C, Lestavel S, Torpier G, van der Veen J, Touche V, Bultel S, Yous S, Kuipers F, Paumelle R, Fruchart JC, Staels B, Tailleux A: The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2731-7. Epub 2006 Sep 28. [PubMed:17008586 ]
  5. Yen WC, Lamph WW: The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma. Mol Cancer Ther. 2005 May;4(5):824-34. [PubMed:15897247 ]
  6. Yen WC, Prudente RY, Corpuz MR, Negro-Vilar A, Lamph WW: A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours. Br J Cancer. 2006 Mar 13;94(5):654-60. [PubMed:16495926 ]
  7. Rizvi N, Hawkins MJ, Eisenberg PD, Yocum RC, Reich SD: Placebo-controlled trial of bexarotene, a retinoid x receptor agonist, as maintenance therapy for patients treated with chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer. 2001 Feb;2(3):210-5. [PubMed:14700480 ]
  8. Rigas JR, Dragnev KH: Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene. Oncologist. 2005 Jan;10(1):22-33. [PubMed:15632250 ]
  9. Farol LT, Hymes KB: Bexarotene: a clinical review. Expert Rev Anticancer Ther. 2004 Apr;4(2):180-8. [PubMed:15056048 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5 (By similarity). Specifically bin...
Gene Name:
RXRB
Uniprot ID:
P28702
Molecular Weight:
56921.38 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Tsai DE, Luger SM, Andreadis C, Vogl DT, Kemner A, Potuzak M, Goradia A, Loren AW, Perl AE, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Thompson JE, Swider C, Bagg A, Mato AR, Carroll M: A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia. Clin Cancer Res. 2008 Sep 1;14(17):5619-25. doi: 10.1158/1078-0432.CCR-07-5185. [PubMed:18765556 ]
  4. Tooker P, Yen WC, Ng SC, Negro-Vilar A, Hermann TW: Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification. Cancer Res. 2007 May 1;67(9):4425-33. [PubMed:17483357 ]
  5. Lalloyer F, Fievet C, Lestavel S, Torpier G, van der Veen J, Touche V, Bultel S, Yous S, Kuipers F, Paumelle R, Fruchart JC, Staels B, Tailleux A: The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2731-7. Epub 2006 Sep 28. [PubMed:17008586 ]
  6. Yen WC, Lamph WW: The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma. Mol Cancer Ther. 2005 May;4(5):824-34. [PubMed:15897247 ]
  7. Yen WC, Prudente RY, Corpuz MR, Negro-Vilar A, Lamph WW: A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours. Br J Cancer. 2006 Mar 13;94(5):654-60. [PubMed:16495926 ]
  8. Rizvi N, Hawkins MJ, Eisenberg PD, Yocum RC, Reich SD: Placebo-controlled trial of bexarotene, a retinoid x receptor agonist, as maintenance therapy for patients treated with chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer. 2001 Feb;2(3):210-5. [PubMed:14700480 ]
  9. Rigas JR, Dragnev KH: Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene. Oncologist. 2005 Jan;10(1):22-33. [PubMed:15632250 ]
  10. Farol LT, Hymes KB: Bexarotene: a clinical review. Expert Rev Anticancer Ther. 2004 Apr;4(2):180-8. [PubMed:15056048 ]
  11. Lowe MN, Plosker GL: Bexarotene. Am J Clin Dermatol. 2000 Jul-Aug;1(4):245-50; discussion 251-2. [PubMed:11702369 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. The high affinity ligand for RXR...
Gene Name:
RXRG
Uniprot ID:
P48443
Molecular Weight:
50870.72 Da
References
  1. Lowe MN, Plosker GL: Bexarotene. Am J Clin Dermatol. 2000 Jul-Aug;1(4):245-50; discussion 251-2. [PubMed:11702369 ]
  2. Tsai DE, Luger SM, Andreadis C, Vogl DT, Kemner A, Potuzak M, Goradia A, Loren AW, Perl AE, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Thompson JE, Swider C, Bagg A, Mato AR, Carroll M: A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia. Clin Cancer Res. 2008 Sep 1;14(17):5619-25. doi: 10.1158/1078-0432.CCR-07-5185. [PubMed:18765556 ]
  3. Tooker P, Yen WC, Ng SC, Negro-Vilar A, Hermann TW: Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification. Cancer Res. 2007 May 1;67(9):4425-33. [PubMed:17483357 ]
  4. Lalloyer F, Fievet C, Lestavel S, Torpier G, van der Veen J, Touche V, Bultel S, Yous S, Kuipers F, Paumelle R, Fruchart JC, Staels B, Tailleux A: The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2731-7. Epub 2006 Sep 28. [PubMed:17008586 ]
  5. Yen WC, Lamph WW: The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma. Mol Cancer Ther. 2005 May;4(5):824-34. [PubMed:15897247 ]
  6. Yen WC, Prudente RY, Corpuz MR, Negro-Vilar A, Lamph WW: A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours. Br J Cancer. 2006 Mar 13;94(5):654-60. [PubMed:16495926 ]
  7. Rizvi N, Hawkins MJ, Eisenberg PD, Yocum RC, Reich SD: Placebo-controlled trial of bexarotene, a retinoid x receptor agonist, as maintenance therapy for patients treated with chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer. 2001 Feb;2(3):210-5. [PubMed:14700480 ]
  8. Rigas JR, Dragnev KH: Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene. Oncologist. 2005 Jan;10(1):22-33. [PubMed:15632250 ]
  9. Farol LT, Hymes KB: Bexarotene: a clinical review. Expert Rev Anticancer Ther. 2004 Apr;4(2):180-8. [PubMed:15056048 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 26, 2016 02:13